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The GATA family of transcription factors are known to play multiple critical roles in vertebrate developmental processes, including
erythropoiesis, endoderm formation and cardiogenesis. There have been no previous demonstrations of a functional role for any GATA family
member being associated with musculoskeletal development but we now identify a possible role for GATA-6 in chondrogenesis. We detect
abundant levels of GATA-6 mRNA in precartilaginous condensations (PCCs) in both the axial and appendicular skeleton of mouse embryos and in
committed primary chondrocyte precursors. We also show that the G-protein coupled receptor, Gpr49, is a target of GATA-6 regulation in
differentiating embryonal carcinoma cells and that, in vivo, the expression domains of the two genes overlap within PCCs. Finally, we have
identified conserved, canonical GATA binding sites within the Gpr49 gene locus, and show by EMSAs that GATA-6 can bind to these sites in
vitro. These data therefore suggest that GATA-6 also plays a role in chondrogenesis and that Gpr49 is a potential direct target of GATA regulation
in this process.
© 2007 Elsevier Inc. All rights reserved.Keywords: Chondrogenesis; GATA factors; Embryogenesis; Transcription factor; G-protein-coupled receptor; ATDC5 cellsIntroduction
Transcription factors of the GATA family are zinc-finger
DNA-binding proteins which recognise the consensus sequence
(T/A)GATA(A/G) and mediate a broad range of cellular
processes including differentiation and homeostasis (for
reviews, see Bresnick et al., 2005; Peterkin et al., 2005).
GATA factors can be subdivided into two subfamilies, GATA-1,
-2, -3 and GATA-4, -5, -6, based on sequence homologies and
tissue distribution. Originally, the first family was thought to be
generally restricted to blood lineages and the second group
mainly confined to endoderm derivatives and heart. However, it
is now clear that their distribution is much more widespread
and, in addition to the tissues mentioned above, expression of
GATA factors has additionally been detected in the nervous
system, testis, ovary, adrenal gland and smooth muscle among⁎ Corresponding author. Fax: +44 (0)20 7848 6569.
E-mail address: john.pizzey@kcl.ac.uk (J.A. Pizzey).
0012-1606/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2007.12.001other tissues (see, for example, Brewer et al., 1999; Morrisey et
al., 1996; Viger et al., 2004). Despite this relatively wide
distribution, no GATA factor has been shown to be associated
with chondrogenesis.
Here, we initially investigated our earlier observations that
GATA-6 could be detected within the sclerotome (Brewer et al.,
2002) to determine whether this might reflect a role for GATA-6
in the chondrogenic process. We now show that GATA-6 is
highly expressed in PCCs throughout the embryo as well as in
prechondrocytes in vitro, suggesting an important function for
this transcriptional regulator in cartilage development.
Most skeletal elements originate from loosely packed
mesenchymal cells which condense into precartilaginous con-
densations (PCCs) in response to extracellular cues (Goldring et
al., 2006; Lefebvre and Smits, 2005). In endochondral ossification
(which is responsible formost bone formation), chondroblasts and
prechondrocyteswithin PCCs then differentiate into chondrocytes
forming a matrix in which they proliferate, differentiate and
subsequently hypertrophy. The apoptosing hypertrophic chon-
458 A. Alexandrovich et al. / Developmental Biology 314 (2008) 457–470drocytes are then replaced by colonising osteoblasts (Kronenberg,
2003). By contrast, in intramembranous ossification, character-
istic of the viscerocranium forming the facial skeleton, mesench-
ymal cells differentiate directly into osteoblasts and ossification
proceeds without the requirement of a cartilaginous matrix
(Karsenty, 2003).
The prechondrocyte precursors of the endochondral ossifica-
tion process have multiple origins within the early embryo
depending upon which skeletal elements they will eventually
contribute to. Thus, much of the skull is of neural crest or
occipital sclerotomal origin, the bony and cartilaginous
components of the vertebral column arise from trunk scler-
otome, whereas the cartilaginous primordia of the limbs
originate from the lateral plate mesoderm. Despite the
heterogeneity in the origins of the cartilaginous precursors,
the mechanisms of chondrogenesis and subsequent ossification
are largely conserved in different sites within the embryo.
Although this suggests that the genetic mechanisms are
similarly conserved, the molecular basis for these events
remains relatively poorly understood. In particular, although
much progress has been made in recent years, notably the roles
played by Runx and SOX genes among others (see Discussion),
relatively little remains known of the transcriptional mechan-
isms which regulate the tissue- and development stage-
restricted patterns of gene expression during chondrogenesis
(Provot and Schipani, 2005).
As a first step in elucidating a potential role for GATA-6 in
this process, we have investigated the distribution of GATA-6 in
the mouse embryo during early chondrogenesis. We have also
utilised data from a previous oligonucleotide microarray screen
that we performed to identify potential transcriptional targets of
GATA-6 in differentiating embryonal carcinoma (EC) P19 cells
(Alexandrovich et al., 2006). One of the candidate genes
identified by this approach is a member of the glycoprotein
hormone receptor family, the orphan G-protein-coupled recep-
tor (GPCR), Gpr49 (Hermey et al., 1999; Hsu et al., 1998). This
gene has also previously been implicated in development of the
vertebral column (Hermey et al., 1999). We have now validated
the microarray findings by quantitative PCR (qPCR), and
further demonstrate by in situ hybridization, genomic analyzes,
electrophoretic mobility shift assays (EMSAs) and siRNA
inactivation experiments that Gpr49 may be a direct target of
GATA-6 regulation in cartilaginous precursor cells. Thus, in
addition to establishing a major novel tissue in which GATA
factors have a developmental role, we have also begun to
identify one of the potential downstream effectors of GATA-6 in
this process.
Materials and methods
Cell culture and transfection
P19 CL6 cells were a kind gift of Issei Komuro and were cultured and
induced to differentiate along cardiac lineages as previously described (Brewer
et al., 2005; Hosoda et al., 2001). Transient transfections to overexpress mouse
GATA-6 in these cells, and microarray analyzes have been described previously
(Alexandrovich et al., 2006). To generate stable siRNA transfected cell lines,
cells were seeded at 50% confluency, 24 h prior to transfection in 6-well plates.Each well was transfected using 4 μg total plasmid DNA and 8 μl Lipofectamine
2000 (Invitrogen), according to the manufacturer’s instructions. Cells were
selected and subsequently maintained in culture medium supplemented with
400 μg/ml Geneticin (Invitrogen).
ATDC5 cells were maintained as described previously (Thomas et al., 2000)
in 1:1 DMEM/F12 (Invitrogen) containing 5% batch-tested FCS (Autogen
Bioclear) and supplemented with bovine insulin (10 μg/ml), human transferrin
(10 μg/ml) and sodium selenite (3×10−8M) (all from Sigma). For differentiation
and transfection experiments, cells were plated at a density of 6×104 cells/well
of 6-well plates and cultured for 18 days. Differentiation was confirmed by
staining cultures after 15–18 days with 0.25% Alcian Blue at pH 0.75. Cells
became 90–95% confluent 4 days after plating at the density given above. These
near-confluent cultures correspond to the onset of differentiation (Atsumi et al.,
1990) and are referred to here as day 0. Transfection of ATDC5 cells was
performed 3 days later and RNAwas isolated from the confluent cultures after
24 h (day 4) using the same procedures as for P19 CL6 cells described above. In
other experiments, RNAwas collected from untransfected ATDC5 cells at day 0
and day 4.
Transfection constructs
The full-length GATA-6 expression construct, pLINK-G6, comprising the
complete mouse GATA-6 coding sequence, has been described previously
(Brewer et al., 2005). For generating the stable GATA-6 knockdown P19 CL6
cell line, sequence unique to the coding region of mouse GATA-6 (Table 1) was
cloned into BamHI and HindIII sites of pSilencer 3.1-H1 neo vector (Ambion),
resulting in pSG6p. The original pSilencer 3.1-H1 neo vector, which includes
negative control siRNA template, was used to generate a control stable P19 CL6
cell line. For ATDC5 cells, cells were transfected with either pLINK-G6 or
control pLINK vectors.
qPCR analysis
Total P19 CL6 or ATDC5 RNA was reverse transcribed, using random
decamers, with AMV RT (Promega) according to the manufacturer’s protocol.
Control reactions, omitting AMV RT, were also performed. Relative expression
levels of the specific transcripts were quantified by qPCR using fluorescent
SYBR Green I technology on the ABI PRISM 7000 HT sequence detection
system (Applied Biosystems), and normalised to those of ribosomal 18S or
cytoskeletal β-actin RNA as described. Primers were designed using the Primer
Express software (Applied Biosystems) with default settings, applied to mouse
cDNA sequences derived from the NCBI Web site (http://www.ncbi.nlm.nih.
gov), and are shown in Table 1. In general, each experiment was repeated in
triplicate and assayed at least in duplicate using the comparative Ct method as
described previously (Brewer et al., 2006; Winer et al., 1999). Where the relative
expression levels of several genes within one sample were analyzed, the same
threshold Ct was set for all primers.
RNA was also extracted from primary prechondrocyte cultures which were
established from neonatal mouse costal cartilage and subsequently maintained
with modifications (Grigoriadis, unpublished) to the protocols described
previously (Lefebvre et al., 1994).
In situ hybridization
The mouse GATA-6 probe was prepared as previously described (Brewer et
al., 1999). The mouse Uncx4.1 probe template was a kind gift of Dr. Ahmed
Mansouri and was described previously (Mansouri et al., 1997). A 1.5-kb Gpr49
fragment was generated by PCR using cDNA from P19 CL6 cells over-
expressing GATA-6 (Alexandrovich et al., 2006) and primers as shown in Table
1. This product was cloned into pGEM T Easy (Promega), linearised with
HindIII, and transcribed with SP6 RNA Polymerase (Roche). All riboprobes
were labelled with dig-11-UTP using the DIG RNA Labelling Kit (SP6/T7)
(Roche) according to the manufacturer’s instructions. Efficiency of the labelling
reaction was checked using a standard dot-blot assay.
For day 12.5 (E12.5) mouse embryos, in situ hybridization was carried out
on 6-μm sections of day 12.5 (E12.5) mouse embryos, using modifications of
previously described protocols (Moorman et al., 2001). Briefly, embryos were
Table 1
Oligonucleotides used in the experiments
qPCR
Gene name Forward primer 5'–3' Reverse primer 5'–3'
GATA-1 TGCCCCAGTTTGTGGATTCT CCCTCTGGCCCAGAGGAA
GATA-2 GCCGTATTGAATGCGCAGTA TGCTGGCTCCATGTAGTTATGC
GATA-3 CAACCACGTCCCGTCCTACT TGGTGGGTCGGAGGATACC
GATA-4 GGGCCAACCCTGGAAGAC GCCCCACAATTGACACACTCT
GATA-5 CGCTAGTGAGGCCCCAAAA GGCAGTTGGAGCAGCATAGG
GATA-6 GAAGCGCGTGCCTTCATC GTAGTGGTTGTGGTGTGACAGTTG
Gpr49 TCGGACGATGTTGAGAAACG GCTGGCGTGGGTAAAGGATA
Col2a1 (Col II) AAGTCACTGAACAACCAGATTGAGA AAGTGCGAGCAGGGTTCTTG
SOX-9 CGGCTCCAGCAAGAACAAG TGCGCCCACACCATGA
Ihh CCACCTTCAGTGATGTGCTTATTT CGATGACCTGGAAAGCTCTCA
PTHrP CTTGCGCCGCCGTTT TCTGATTTCGGCTGTGTGGAT
18S CCCAGTAAGTGCGGGTCATAA CCGAGGGCCTCACTAAACC
GAPDH TGTGTCCGTCGTGGATCTGA CCTGCTTCACCACCTTCTTGA
β-actin CGTGAAAAGATGACCCAGATCA TGGTACGACCAGAGGCATACAG
siRNA
Forward oligonucleotide 5'–3' Reverse oligonucleotide 5'–3'
GATA-6 siRNA template GATCCGTGCGTTGCAGCAATCAGTGTTCAAGA
GACACTGATTGCTGCAACGCATTTTTTGGAAA
AGCTTTTCCAAAAAATGCGTTGCAGCAATCAG
TGTCTCTTGAACACTGATTGCTGCAACGCACG
In situ hybridization
Forward primer 5'–3' Reverse primer 5'–3'
Gpr49 probe AGATAAAGCTTATGGACACCTCCT AGATACTCGAGGCCGTCGTCTTTA
GCGTCCA TTCCATT
Electrophoretic mobility shift assay
Forward oligonucleotide 5'–3' Reverse oligonucleotide 3'–5'
Gpr49 site 1 CTCTGGTCAGATAAATCTCACT GAGACCAGTCTATTTAGAGTGA
Gpr49 site 1 mut CTCTGGTCTTTAAAATCTCACT GAGACCAGAAATTTTAGAGTGA
Gpr49 site 2 GATCAAAAAGATAAACTAATTT CTAGTTTTTCTATTTGATTAAA
Gpr49 site 2 mut GATCAAAATTTAAAACTAATTT CTAGTTTTAAATTTTGATTAAA
αG2 (GATA) GATCCGGGCAACTGATAAGGATTCCCA CTAGGCCCGTTGACTATTCCTAAGGGT
Sp1 ATTCGATCGGGGCGGGGCGAGC TAAGCTAGCCCCGCCCCGCTCG
Sequence details of the oligonucleotides used. Sequence information is given for primers used for the qPCR reactions and the PCR reaction performed to generate the
template for the Gpr49 riboprobe. Also shown are the oligonucleotide template sequence for the GATA-6 siRNA studies and the sequence of the primers used for
EMSAs.
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sectioned. Sections were rehydrated through graded ethanols, re-fixed in
4% paraformaldehyde for 15 min and treated with 10 μg/ml Proteinase K
(Sigma–Aldrich) for 5 min. Digestion was stopped with 2 mg/ml glycine/
PBS for 5 min, sections were postfixed for 15 min in 4% paraformaldehyde
and then pre-hybridized in hybridization buffer (50% Formamide/1.3× SSC
pH 4.5/5 mM EDTA/50 μg/ml yeast RNA/0.2% Tween-20/0.5% CHAPS/
100 μg/ml heparin) for 30 min at 65 °C. Sections were hybridized overnight
at 70 °C in hybridization buffer containing 0.4 μg/ml DIG-labelled RNA
probe.
Sections were washed 3×15 min at 65×°C in 50% formamide/5× SSC pH
4.5/1% SDS, followed by 3×15 min high stringency washes (50% formamide/
2× SSC pH 4.5) at 65×°C. Sections were then washed 3×10 min in TBST
(25 mM Tris–Cl pH 7.5/137 mM NaCl/2.7 mM KCl/0.1% Tween-20), blocked
for 30 min at 4 °C with MABT (100 mM maleic acid pH 7.5/150 mM NaCl/1%
Tween-20) containing 10% heat-inactivated sheep serum and incubated
overnight in MABT/10% serum containing 0.05% anti-DIG antibody
(Roche). Next day, sections were washed in TBST and equilibrated in NTMT
(100 mM Tris–Cl pH 9.5/100 mM NaCl/50 mM MgCl2/0.1% Tween-20).
Colour reactions were developed in NBT/BCIP (Roche) in NTMTat 4 °C for 1–
3 days. In situ hybridization was also carried out on sections from E15.5 mouse
embryos. In these studies, collagen (Lanske et al., 1996) and GATA-6riboprobes were used following a modification of the procedure described in
Gack et al. (1995).Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from untransfected and pLINK-G6-
transfected Cos-7 cells using the NE-PER kit (Pierce), in accordance with the
manufacturer’s recommendations, as described previously (Alexandrovich et
al., 2006;Brewer et al., 2006). Complementary single-stranded oligonucleotides
(Table 1) were annealed at 1 μM in 100 mM NaCl/10 mM Tris–HCl (pH 8.0)/
1 mM EDTA.
Double-stranded (ds) oligonucleotides (Gpr49 site 1, Gpr49 site 2 and αG2)
were radiolabelled at their 5′ termini using [γ-32P] dATP (3 kCi/mM, GE
Healthcare) and T4 polynucleotide kinase (Promega). Each 20-μl assay mix
contained 20 fmol ds radiolabelled oligonucleotide probe, 4 pmol ds unlabelled
competitor oligonucleotide (as necessary), 6 μg protein extract in a buffer
comprising 10 mM Tris–HCl (pH 7.5)/50 mM KCl/5 mM MgCl2/1 mM DTT/
150 μg/ml poly dIdC/10% glycerol. Reactions were pre-incubated at room
temperature for 20 min before addition of the radiolabelled probe and,
subsequently, incubated for a further 20 min. DNA–protein complexes were
resolved on 6% non-denaturing TBE polyacrylamide gels, containing 10%
460 A. Alexandrovich et al. / Developmental Biology 314 (2008) 457–470glycerol, which were vacuum-dried and exposed to X-ray film for autoradio-
graphic detection.
Bioinformatics
Homologous regions of the Gpr49 promoters and first intron of human,
chimpanzee, mouse and rat (Ensembl Gene IDs ENSG00000139292,
ENSPTRG00000005223, ENSMUSG00000020140 andENSRNOG00000004221,
respectively) were aligned by using the multiple alignment tool ClustalW at
http://www.ebi.ac.uk/clustalw/ with the default settings. GATA transcription
factor binding sites within the Gpr49 gene loci were explored with the ConSite
tool available at http://mordor.cgb.ki.se/cgi-bin/CONSITE/consite.
Results
GATA-6 is expressed in precartilaginous condensations in the
embryonic axial skeleton
To determine whether our previous observations on the
sclerotome expression of GATA-6 protein (Brewer et al., 2002)
represented a role for GATA-6 in chondrogenic vertebral
precursors, we performed in situ hybridization experiments on
parasagittal sections of E12.5 mouse embryos (Fig. 1A). This
stage was chosen for study as it represents a stage when multiple
sites of PCCs are found throughout the embryo (Kaufman,
1999; Lefebvre and Smits, 2005). Consistent with previous
findings from ourselves (Brewer et al., 1999) and others
(Morrisey et al., 1996), strong expression of GATA-6 RNA is
seen in multiple tissues including umbilical vein, gut, and heart.
In the heart, the highest levels of expression are seen within the
endocardial cushions and isolated, individual cells within the
myocardium (Fig. 1B). It is also apparent from Fig. 1A that
GATA-6 expression extends throughout the length of the
vertebral column. Closer examination of this expression pattern
reveals that, in the thoracic prevertebrae at this stage, labelling is
not uniform (Fig. 1C). Rather, GATA-6 expression is weak or
absent within the more mature centres of the prevertebral
primordia that will give rise to the transverse processes and
neural arches. These centres contain the more differentiated
prehypertrophic and hypertrophic chondrocytes and, therefore,Fig. 1. Widespread expression of GATA-6 at sites of chondrogenesis in mouse embryo
6 expression including domains in the umbilical vein (uv) and epithelia of the
chondrogenesis. Expression is seen in the walls of Meckel's cartilage (m) and through
expressed in each of the prevertebrae; the first prevertebra for cervical (C1), thor
orientation. (B) Enlargement of (A) showing cardiac expression of GATA-6. Strong
the myocardium (arrowed). (C) Enlargement of (A) showing GATA-6 expression in t
the developing transverse processes (tp) and neural arches (na) of the prevertebrae. GA
weaker (in the more rostral prevertebrae at this level, see also panel A) in the centres w
the corresponding dorsal root ganglia (drg). (D) Enlargement of (A) showing GATA
through the midline at this level as shown by the presence of the notochord (n). G
GATA-6 expression can be seen in the underlying spinal cord (sc). (E, F) In situ h
showing expression of GATA-6 (E) and Uncx4.1 (F). The expression domains broadl
extends into the pedicle (p) and head of the rib (r). (G) Enlargement of (A) showing G
dorsal region of the basio-occipital bone, the atlas (C1) and axis (C2). Sclerotomal ce
(H) Serial section to (E) following in situ hybridization with a Coll II riboprobe. The
in both the prevertebral centrum (c) and extending into the pedicles (p). (I–K) In situ h
showing expression of GATA-6 (I), Coll II (J) and Coll X (K). In panels I and K, labe
flanking the central region of hypertrophic chondrocytes (HC) which is negative. In p
hypertrophic cells.GATA-6 expression may be down-regulated as chondrocytes
mature (see below).
Within the prevertebrae of the more inferior vertebral
column, however, the labelling is more uniform, with no
evidence of foci of hypertrophic chondrocytes (Fig. 1D). As
indicated by the presence of the notochord in this image, the
section passes closer to the midline here, and thus, through the
primordia of the prevertebral bodies (centra) rather than the
primordia of the transverse processes and neural arches. The
process of chondrocyte maturation and replacement is known to
occur first in dorsal vertebral elements and later in the centra; in
general, maturation of the centra occurs approximately 2 days
later than the rest of the prevertebrae (Kaufman, 1999). Thus,
the strong staining seen throughout the centra at this stage is
consistent with the hypothesis that GATA-6 is more abundant in
less differentiated prechondrocyte populations. It should also be
noted that prevertebrae in the more inferior vertebral column are
more immature than those in thoracic regions as a consequence
of the rostro-caudal direction of somatic development but this
does not account for the different pattern of labelling here.
Indeed, uniform expression of GATA-6 within the centra was
seen at all vertebral levels in E12.5 embryos (Figs. 1A, D and
data not shown).
Confirmation of expression of GATA-6 in the centra is
shown in Fig. 1E with co-expression shown with Uncx4.1 in
Fig. 1F. The sclerotome is originally segmented such that
specific domains give rise to primordia of different vertebral
elements (for a review, see Rice and Dietrich, 2006). Thus,
Uncx4.1 is expressed in the caudal half of the sclerotome
(Mansouri et al., 1997) from which the pedicle, neural arch and
transverse process derive while the centra and spinous process
originate from both caudal and rostral halves of the sclerotome
(Gossler and Hrabe, 1998; Yamaguchi, 1997). Figs. 1E, F
demonstrate that GATA-6 is highly expressed in the centra and
largely overlaps with Uncx4.1 both here and also in the pedicle
and head of the rib, although the expression domain of Uncx4.1
appears broader.
The Uncx4.1 data might be consistent with GATA-6 ex-
pression being restricted to the caudal sclerotome compartment.s. (A) In situ hybridization of a sagittal section showing multiple sites of GATA-
duodenum (d). Additionally, GATA-6 expression is seen at multiple sites of
out the basio-occipital bone (bo). In the vertebral column, GATA-6 is seen to be
acic (T1), lumbar (L1), sacral (S1) and caudal (Ca1) regions are labelled for
expression is seen in the endocardial cushions (ec) and in individual cells within
he thoracic vertebral column. The section here is parasagittal and passes through
TA-6 expression is absent from the centres of the neural arch condensations and
hich will give rise to the transverse processes. No GATA-6 expression is seen in
-6 expression in the sacral/caudal vertebral column. The plane of section passes
ATA-6 expression is uniform throughout the centra (c) of the prevertebrae. No
ybridization of serial transverse sections through the thoracic vertebral column
y overlap with the centra of the prevertebrae uniformly labelled. Expression also
ATA-6 expression in the superior vertebral column. Expression is shown in the
lls from the fifth somite (S5) can be seen still contributing to both prevertebrae.
expression pattern is similar to that of GATA-6 with Coll II transcripts detectable
ybridization of serial longitudinal sections through the femur of an E15.5 mouse
lling is largely associated with the proliferating chondrocyte precursors (asterisk)
anel K, the converse is true and Coll X expression is confined to the more mature
461A. Alexandrovich et al. / Developmental Biology 314 (2008) 457–470However, we believe that this is unlikely because GATA-6
appears to be distributed throughout the rostro-caudal length
of the prevertebrae. This is particularly clear for C1 (atlas) and
C2 (axis) shown in Fig. 1H. In addition, GATA-6 labelling
can also be seen in the sclerotomal derivatives of the fifth
somite, which contribute to both the caudal and rostral aspects
of C1 and C2, respectively (Fig. 1G). Also in this figure,
GATA-6 expression can be seen in the dorsal part of the
basio-occipital bone. From Fig. 1A it can be seen that the
expression extends throughout the basio-occipital bone and
also to other elements of the chondrocranium, including
Meckel’s cartilage, which will give rise to the mandible and the
malleus of the middle ear. Thus, GATA-6 is not only associatedwith chondrogenesis at multiple sites within the embryo but
also with chondrocytes derived from different lineages (see
Discussion).
To address directly whether GATA-6 is associated with
immature proliferating chondrocytes, by contrast to mature,
hypertrophic chondrocytes, we compared the expression of
Collagen type II (Coll II) and Collagen type X (Coll X), which
respectively mark these two populations, with that of GATA-6
in sites of chondrogenesis. Sections serial to those in Figs. 1E, F
demonstrate that Coll II largely co-localises with GATA-6
(Fig. 1H), whereas Coll X could not be detected at this stage
(data not shown). This indication that GATA-6 is preferentially
associated with immature chondrocytes was further investigated
Fig. 3. Expression of GATA-6 and chondrogenic markers in ATDC5 cells.
(A and B) qPCR analyses of mRNAs isolated from ATDC5 cells harvested at
day 0 or day 4. Levels of gene expression indicated are shown normalised to
GAPDH, and relative to the level of expression of Ihh at day 0 in each case.
462 A. Alexandrovich et al. / Developmental Biology 314 (2008) 457–470by comparing GATA-6, Coll II and Coll X in developing
limbs in E15.5 embryos. GATA-6 showed an overlapping
expression domain with Coll II-expressing proliferating
chondrocytes with little or no expression in the hypertrophic
chondrocytes which express Coll X (Figs. 1I–K). The overall
expression levels of GATA-6 in chondrocyte precursors also
appeared to be lower at E15.5 than at E12.5, suggesting that
GATA-6 is under tight developmental regulation in these cells.
Thus, in addition to being the first report of any GATA factor
being associated with skeletal development, these results also
confirm that GATA-6 is predominantly expressed during early
stages of chondrogenesis and becomes down-regulated during
chondrocyte differentiation.
GATA-6 is associated with chondrogenesis in vitro
As GATA-6 is the only GATA factor reported so far to be
expressed within PCC, we first established whether this is the
only GATA factor expressed by chondrogenic cells, the major
constituent cells in such mesenchymal condensations. To
achieve this, we performed qPCR on RNA extracted from
primary mouse chondrocyte cultures derived from neonatal
mouse costal cartilage, which represent a population of
committed chondrocyte precursors (Lefebvre et al., 1994).
As shown in Fig. 2, GATA-6 was confirmed to be highly
expressed (at approximately 0.1% of the level of the ribosomal
18S gene) in these cells. No expression of GATA-1,-3,-4 or -5
could be detected and only low levels of GATA-2 (more than
200-fold less than those of GATA-6) were found. The
significance of this GATA-2 expression is unknown but the
procedures for establishing the cultures make it unlikely that
this reflects contaminating immature haematopoietic cells,
which are known to express GATA-2 (Tsai et al., 1994).Fig. 2. GATA-6 is the most abundant GATA factor in primary prechondrocyte
cultures. (A) Relative expression of GATA factors in primary prechondrocyte
cultures, determined by qPCR. GATA-6 is clearly the highest expressed GATA
factor. Only low levels of GATA-2 RNA are detectable while the expression of
the remaining GATA factors is not above background levels. (B) Agarose gel
electrophoresis of the corresponding qPCR reactions shown in panel A above.
The strong GATA-6 band demonstrates that the quantitation performed in panel
A is the consequence of a genuinely amplified product and not artifactual.
Similar confirmation is indicated by the weak GATA-2 product and the absence
of a signal in the remaining lanes. M, marker lane.However, it is clear from these data that GATA-6 is, by far, the
most abundant GATA family member expressed in these
prechondrocyte cultures. Further, unlike some other embryonic
programmes such as the developing heart and the gut (Brewer
and Pizzey, 2006; Nemer and Nemer, 2003), no substantial co-
expression of GATA-6 with GATA-4 or -5 is seen in these cells.
We next established the relationship between the expression
of GATA-6 and known chondrogenic genes by determining
quantitatively their expression in ATDC5 cells, which have
been widely used as an in vitro model system for chondrogen-
esis (Atsumi et al., 1990; Shukunami et al., 1996). Because
GATA-6 appears to be associated with the earliest stages of
chondrogenesis in vivo, we compared its pattern of expression
with that of a panel of known chondrogenic genes during the
early induction of ATDC5 cells (Atsumi et al., 1990); Coll II,
the SRY-box containing gene, SOX-9, the signalling molecule,
Indian Hedgehog (Ihh) and the parathyroid hormone-related
protein (PTHrP). Each of these genes has been shown to be
involved directly at different stages of chondrocyte differentia-
tion in vivo (see, for example, de et al., 2001; Karsenty and
Wagner, 2002). Thus, SOX-9 first appears during mesenchymal
cell condensation and is maintained through subsequent
prechondrocyte differentiation. Col II is similarly present from
the earliest stages of chondrogenesis and subsequently declines
in prehypertrophic and hypertrophic chondrocytes while Ihh
and PTHrP are first expressed in prehypertrophic cells (for a
review, see Goldring et al., 2006). Correspondingly, in the
ATDC5 in vitro model of chondrogenesis, high levels of Col II
and SOX-9 expression have been shown previously to precede
463A. Alexandrovich et al. / Developmental Biology 314 (2008) 457–470an increase in Ihh and PTHrP expression, which in turn
precedes Col X up-regulation (Chen et al., 2005). In the
experiments described here, levels of Coll II mRNA in ATDC5
cells were initially high, and increased significantly during the
first 4 days of induction, indicating differentiation along the
chondrogenic pathway as expected (Fig. 3, panel A). In
addition, the cells also expressed high levels of SOX-9 and
these levels remained high during the induction period.
Expression of the other genes studied here was approximately
100- to 1000-fold less than the levels of SOX-9 and Col II at day
0, and thus, the relative expression of all genes shown in Fig. 3
is related to the RNA level of Ihh at day 0. Although initially
low, the levels of Ihh RNA also increased over the time period,
while levels of PTHrP did not change (Fig. 3). The levels and
changes in gene expression seen here are therefore in general
agreement with those reported previously to represent an early
stage of chondrogenic differentiation (Chen et al., 2005). That
GATA-6 mRNA levels were found to increase significantly
(approximately 2.5-fold) during this time period, before any
change in expression of either PTHrP or Col X (Fig. 3, panel B
and data not shown) is therefore consistent with a role for
GATA-6 in prechondrocytes in vivo.
To attempt to determine the functional significance of the
increase of endogenous GATA-6 expression seen in earlyFig. 4. Gpr49 is a potential target of GATA-6 regulation. (A) qPCR analyses of mRNA
the GATA-6 expression vector pLINK-G6 at day 3 of induction and harvested at da
analyses of mRNAs isolated from induced P19 CL6 cells stably transfected with contr
6 of induction. The levels of expression of GATA-6, Gpr49, cytoskeletal β-actin and G
18S RNA in each case. (F) qPCR analyses of mRNAs isolated from ATDC5 cells har
and Gpr49 expression are normalised to GAPDH, and relative to the level of expresdifferentiating prechondrocytes, we overexpressed GATA-6 in
ATDC5 cells 7 days after seeding. We harvested the cells 24 h
later, and assayed the mRNA levels of the panel of chon-
drogenic genes described above, to determine any changes
dependent upon forced expression of GATA-6. However, we
detected no change in the expression of Col II, Col X, PTHrP,
Ihh or SOX-9 in these experiments (data not shown), suggesting
that GATA-6 expression alone is not sufficient to change the
differentiation status of these cells. The GATA-6 expression
construct used here has been shown by us to be effective at
trans-activation (see Fig. 4 and Alexandrovich et al., 2006;
Brewer et al., 2005), while efficient gene transfer in these
experiments was confirmed by co-transfection with a GFP
reporter. The significance of these results is considered in the
Discussion.
Gpr49 is a candidate transcriptional target of GATA-6
In order to identify possible transcriptional targets of
GATA-6, we have recently performed an oligonucleotide
microarray screen in which we analyzed the consequences of
forced expression of GATA-6 upon the transcriptomes of
pluripotential EC cells that had been induced to differentiate
(Alexandrovich et al., 2006). Our primary aim in that studys isolated from induced P19 CL6 cells transfected with either control pLINK or
y 4. GATA-6 levels are shown normalised to cytoskeletal β-actin. (B–E) qPCR
ol or GATA-6-specific siRNA-expressing constructs. Cells were harvested at day
APDH in control and knock-down cells are shown relative to levels of ribosomal
vested at day 0 or day 4 following plating in induction media. Levels of GATA-6
sion of Ihh at day 0 (see Fig. 3).
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within the heart. We therefore used a clonal derivative of the
P19 EC cell line, P19 CL6, which has been demonstrated to be
able to be induced to differentiate preferentially along
mesodermal lineages, particularly cardiomyocytes and their
precursors (Habara-Ohkubo, 1996). We identified 103 distinct
genes whose expression was altered (either up- or down-
regulated) at least 2-fold as a consequence of GATA-6
overexpression. As expected, the majority of these genes are
known to be expressed within the heart. One of the genes
identified to be most highly up-regulated by GATA-6 in this
screen was the GPCR, Gpr49 (Hermey et al., 1999). Although
in this latter report Gpr49 RNA was not found to be expressed
in the heart, transcripts were detected transiently in various
other embryonic domains during periods of active morphogen-
esis. These included sites associated with the developing
vertebral column (see below), one of the novel chondrogenic
expression domains of GATA-6 reported here.
In order to confirm that Gpr49 is a (direct or indirect) target
of GATA-6 regulation within (presumably a subset of)
differentiating P19 CL6 EC cells, we quantitated the relative
changes in the mRNA levels of Gpr49, dependent upon GATA-
6 forced expression, by qPCR. RNA from biological triplicate
samples, comprising P19 CL6 cells that had been induced to
differentiate for 4 days, and had been transfected after 3 days
with a GATA-6-expressing plasmid or control vector (and
including those used for the microarray assay), were analyzed.
As shown in Fig. 4A, GATA-6 overexpression resulted in a
highly significant (approximately 30-fold) increase in Gpr49
expression, confirming the data from the microarray analyzes.Fig. 5. GATA-6 and Gpr49 RNA are co-localised in the developing vertebral column a
shown in Figs. 1E, F. Expression of Gpr49 can be seen to coincide with that of GATA-
head of the rib (r). (B) In situ hybridization of Gpr49 in a sagittal section through an
the more dorsal elements which will give rise to the transverse processes (tp). Expressi
(delineated in one example by dashed yellow lines) which lie at the levels of the spin
Gpr49 (C) and GATA-6 (D) in the developing forelimb of an E12.5 mouse embryo.
articulations of the capitulum (c) and trochlea (t) of the humerus.Indeed, by comparison with the fold-increases determined by
qPCR for other similarly identified, GATA-6 up-regulated
genes, the increase in Gpr49 RNA levels represents the third-
highest increase from a total of 26 genes analyzed so far
(Alexandrovich et al., 2006).
To determine further whether Gpr49 is, indeed, a down-
stream target of GATA-6 regulation under normal, physiological
levels of the transcription factor, we generated a stable P19 CL6
polyclonal cell line in which we disrupted the expression of
GATA-6 by siRNA. As shown in Fig. 4B, after 6 days of
DMSO-induced differentiation, the levels of GATA-6 tran-
scripts in the GATA-6 siRNA cells were reduced by
approximately 70%. In the same cells, the levels of Gpr49
transcripts were decreased by approximately 90%, relative to
control cells in each case (Fig. 4C). By contrast, the
housekeeping genes cytoskeletal β-actin (Fig. 4D) and
GAPDH (Fig. 4E) were unaffected (relative to 18S expression)
by the reduction of GATA-6 RNA levels. These data therefore
strongly suggest that Gpr49 is a potential target of GATA-6
regulation under the physiological, endogenous levels of the
transcription factor.
Gpr49 is expressed in prechondrocytes in vitro
As stated above, Gpr49 expression within the mouse embryo
has been found previously at sites associated with the
developing vertebral column (Hermey et al., 1999). To
determine whether this expression might be within prechon-
drocyte lineages, we determined the levels of Gpr49 mRNA
within the ATDC5 in vitro model of early chondrocytend limbs. (A) In situ hybridization of Gpr49 in a transverse section serial to those
6 and Uncx4.1 in the centra (c) and pedicle (p) of the prevertebra as well as in the
E12.5 mouse embryo. Expression can be seen in the prevertebrae, particularly in
on cannot be detected in the dorsal root ganglia (drg) or in the intervertebral disks
al nerves (sn) and intersomitic blood vessels (isv). (D, E) In situ hybridization of
Both genes are expressed in the cartilaginous primordia of the radius (r) and the
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detectable in subconfluent cultures and this expression
increased significantly during their early differentiation. Thus,
the up-regulation of Gpr49 expression mirrored that seen for
GATA-6, although the magnitude of the increase was much
greater (N20-fold for Gpr49, compared to 2.5-fold for GATA-6).
However, despite these similar patterns of expression of GATA-
6 and Gpr49 in ATDC5 cells, and the very marked up-regulation
of Gpr49 following forced expression of GATA-6 in P19 cells,
no such increase in Gpr49 was seen following overexpression of
GATA-6 in ATDC5 cells (data not shown). Although various
possibilities could account for these differences, cell context
and differences in differentiation status are the most probable
reasons as discussed more fully below.
Co-expression of GATA-6 and Gpr49 in PCCs
To determine whether Gpr49 is a potential transcriptional
target of GATA-6 in prechondrocytes in vivo, we performed in
situ hybridization for both transcripts on serial sections of E12.5Fig. 6. Schematic diagram of a sequence alignment of Gpr49 gene loci. The diagra
between mouse, rat, chimpanzee and human. The numbers indicate positions of the po
given in the Ensembl database (http://www.ensembl.org/index.html). Regions I, II an
sites conserved between all four species. Both site 1 and site 2 are within region II
analyzed. The conservation plot shown here represents sequence conservation betwmouse embryos to determine the extent of co-localisation. The
most commonly reported sites of GATA-6 expression during
mouse embryogenesis include the heart, bronchial epithelia of
the lungs, gut epithelia and smooth muscle associated with the
great vessels of the heart, umbilical vessels and gut as
mentioned above. Consistent with previous reports (Hermey
et al., 1999), we were unable to detect Gpr49 in any of these
structures. Rather, we confirmed that the major expression
domains of Gpr49 in E12.5 embryos were elements of the
nervous system and the mandibular cleft (data not shown).
However, we found both Gpr49 and GATA-6 to be co-
expressed in PCC within the centra, pedicle and rib tubercle
(Figs. 1G, 5A). That Gpr49 is expressed in PCCs within the
prevertebrae rather than in the intervertebral disks of E12.5
embryos is confirmed, as the location of the latter are
characterised by the course of the intersomitic vessels and
spinal nerves from the dorsal root ganglia (Fig. 5B).
In addition to PCC within the developing vertebral column,
GATA-6 expression (although weaker) also overlaps with that
of Gpr49 in the limb buds (Figs. 5C, D). Thus, both genes canm shows the positions of potential GATA-6-binding sites, which are conserved
tential GATA-6-binding sites relative to the start of exon 1 of the mouse gene as
d III correspond to three separate regions containing one or more GATA-binding
, which represents the element of highest conservation in the Gpr49 sequences
een mouse and human only.
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radius and the developing capitulum and trochlea of the
humerus at the elbow joint, although as with Uncx4.1 in the
prevertebrae, GATA-6 may represent a more restricted expres-
sion domain or this may simply reflect small changes in the
tissue present in the serial sections. This represents the first
association of both genes with any elements of the developing
limbs and is consistent with Gpr49 being a target of GATA-6
within prechondrocytes in a broad range of embryonic locations.
The Gpr49 gene locus contains canonical GATA binding sites
within conserved regions
In order to determine whether Gpr49 may be a direct
regulatory target of GATA-6, we looked for potential cis-acting
GATA-binding sites within the Gpr49 gene locus. We initially
aligned approximately 160 kb of sequence within the Gpr49 loci
of human and mouse, including 100 kb of sequence upstream of
the known cDNA sequence (available at http://www.ensembl.
org/index.html), together with the entire first intron using the
ClustalWalignment tool as described in Materials and methods.
Using this alignment file, we searched for canonical potential
GATA-binding sites using the ConSite suite of programmes.
Finally, all sites identified in this way were subjected to a
manual search on a global alignment of four mammalian
sequences (human, chimpanzee, mouse and rat), and only those
completely conserved between all four species were considered
for further analyzes. We identified six potential GATA sites,
which fitted our (very stringent) criteria and all fell within threeFig. 7. GATA-6 can bind directly to sites within intron 1 of the Gpr49 gene locus. (A
(αG2) incubated with nuclear extract isolated from control or GATA-6-overexpressing
(B, C) EMSAs using radiolabelled probes corresponding to site 1 or site 2, respect
overexpressing Cos-7 nuclear cell extracts, with or without a 100-fold excess of unlregions of conserved homology, labelled I, II and III in Fig. 6. In
the mouse genome, these domains were found to contain one,
two, and three potential GATA-binding sites, respectively.
Interestingly, no potential GATA sites (fulfilling the above
criteria) are found within 100 kb upstream of the known
transcribed gene sequence. Rather, all are found to occur within
the first intron of the gene. Further, the highest region of
homology between the four aligned mammalian Gpr49 genes
we compared is domain II. This conservation further suggests
functional significance of the two canonical GATA sites
contained within it.
Having identified these two strong candidate GATA-binding
sites within the Gpr49 gene locus, we tested their ability to bind
GATA-6 in vitro using EMSA. An oligonucleotide comprising
a known GATA-binding site from the mouse α globin promoter
(αG2) was radiolabelled and incubated together with nuclear
extract isolated from normal Cos-7 cells (which do not contain
GATA-binding activity; Yokoyama et al., 2003), or from Cos-7
cells transfected with a GATA-6 expressing construct. As seen
in Fig. 7A, the GATA-6 transfected cells contain an activity that
binds to the αG2 oligonucleotide, which is not present in the
normal Cos-7 cells. The specificity of this binding was
demonstrated by competition with a 100-fold excess of
unlabelled oligonucleotide. These same cell extracts were
therefore used to investigate GATA-6 binding to potential
sites within the mouse Gpr49 gene locus. Two separate
oligonucleotides, termed Gpr49 site 1 and Gpr49 site 2
(corresponding to the sites shown in Fig. 6) were radiolabelled
and incubated with either control, or GATA-6-expressing Cos-7) EMSA using a known radiolabelled GATA-binding ds-oligonucleotide probe
Cos-7 cells with or without a 100-fold excess of unlabelled probe as competitor.
ively, within mouse Gpr49 intron 1 incubated with control Cos-7 or GATA-6-
abelled oligonucleotide probe competitor as indicated.
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upon incubation with extract from the GATA-6-expressing
cells (see Fig. 7; compare lanes 1 and 3 in panels B and C). In
both cases, this complex could be efficiently competed by an
excess of unlabelled oligonucleotide (lane 4 in Figs. 7B, C), or
by the known GATA-binding oligonucleotide, αG2 (lane 6 in
Figs. 7B, C). However, the addition of an excess of either
an oligonucleotide representing an Sp1 binding site (lane 7 in
Figs. 7B, C) or an oligonucleotide in which the GATA-motif
had been specifically mutated (lane 5 in Figs. 7B, C) failed to
inhibit formation of the complex in either case. Thus, GATA-6
can clearly bind strongly and specifically to both these sites
within the Gpr49 gene locus.
Discussion
Chondrogenesis represents an essential and very early stage
of skeletal development, providing the formation of cartilagi-
nous primordia which allow for subsequent bone formation via
endochondral ossification. Briefly, migratory mesenchymal
cells are induced to a chondrogenic lineage, become tightly
packed forming condensations, differentiate further, proliferate
and, subsequently, hypertrophy. This occurs in a well-organised
matrix allowing for subsequent invasion of osteoblasts to
replace the hypertrophic chondrocytes which undergo apopto-
sis. As ossification proceeds, most of the original cartilaginous
elements in humans are eventually replaced (for reviews, see
Goldring et al., 2006; Lefebvre and Smits, 2005).
In the early embryo, the original mesenchymal cells derive
from three sources: cranial neural crest, paraxial somitic
mesoderm or lateral plate mesoderm. However, irrespective of
their site of origin, commitment of mesenchymal cells to a
chondrogenic fate requires SOX-9 (Akiyama et al., 2002; Bi et
al., 1999), which is itself dependent upon BMP activity for
expression (Zeng et al., 2002). Subsequent proliferation and
differentiation is associated with sequential activation and/or
repression of specific transcriptional regulators together with
changes in the cell adhesion and matrix molecules expressed
(for a review, see Provot and Schipani, 2005). For example,
repression of SOX-9 is later required for hypertrophic
chondrocyte differentiation (Zhao et al., 1997), while SOX-5
and -6 are broadly co-expressed with SOX-9 but may be more
associated with chondrocyte proliferation or slightly later stages
in chondrogenesis (Lefebvre, 2002). As prechondrocytes
differentiate, there is a requirement for a variety of regulatory
genes including Ihh and PTHrP (Kobayashi et al., 2002; St
Jacques et al., 1999) and fibroblast growth factor signalling.
Here, we report that the transcriptional regulator GATA-6 is
associated with chondrogenesis and appears to be intrinsic to
the chondrogenic process rather than being expressed in a
subset of cartilaginous primordia as we detect GATA-6 in PCCs
derived from all three broad sources of chondrogenic precursors
in the embryo. Thus, we have identified GATA-6 expression in
PCCs in the developing limb (derived from the lateral plate
mesoderm), vertebrae (derived from the paraxial mesoderm of
the sclerotome) and Meckel’s cartilage (of neural crest origin
derived from the first branchial arch).In E12.5 embryos, most of the PCCs present contain early
chondroblasts or prechondrocytes (Lefebvre and Smits, 2005).
In general, GATA-6 was found to be uniformly expressed
throughout these early condensations. An exception at this stage
was within the prevertebrae, where GATA-6 was absent from
the centres of the condensations where ossification will later be
initiated, and therefore, will contain more mature, prehyper-
trophic and hypertrophic chondrocytes. Together with the
overlapping expression profile in developing limbs of GATA-
6 with Coll II, but not Coll X, these observations further support
the notion that GATA-6 is associated with more immature
chondrogenic cells and becomes down-regulated as the cells
differentiate.
GATA-6 broadly overlaps with GATA-4 (and to a lesser
extent GATA-5) in a range of mesodermal and endodermal
derivatives including the myocardium and epithelia of the gut
and lung (Brewer and Pizzey, 2006; Molkentin, 2000). This has
led to the suggestion of some functional redundancy of GATA
function existing in these tissues. However, we suggest that
GATA-6 may be the most important (or only) family member
involved in chondrogenesis. Thus, to date, no in situ
hybridization studies using probes to detect other family
members have revealed expression within sites of chondrogenic
precursors or sites of chondrogenesis. In addition, our qPCR
analyses indicate that GATA-6 is the only abundantly expressed
GATA factor within primary chondrocyte cultures. The
transcriptional repressor trps1 has some weak similarity to
members of the GATA family and is associated with cartilage
condensations in mouse embryos (Kunath et al., 2002). It is
responsible for tricho-rhino-phalangeal syndrome type I in
humans (Momeni et al., 2000) and has recently been shown to
be necessary for chondrocyte proliferation and hypertrophic
chondrocyte apoptosis (Suemoto et al., 2007). However, this
similarity is based only on the observation that 1 of its 9
potential zinc fingers shares some homology with the zinc-
finger DNA-binding domains of GATA factors, and thus, any
relationship to the GATA family is distant.
At present, there are no data on the functional consequences
of ablating GATA-6 expression upon chondrogenesis. This is
due to the early embryonic lethality caused by this mutation.
Thus, GATA-6 null mice die from extraembryonic endoderm
defects by E5.5 (Koutsourakis et al., 1999). In addition, when
this early deficiency is rescued by tetraploid embryo comple-
mentation, GATA-6 null embryos still survive only to E10.5,
due (at least in part) to severe liver defects (Zhao et al., 2005).
Because prechondrocyte aggregation into PCCs does not occur
in the mouse until E11.5–12.5 (Lefebvre and Smits, 2005), any
defects in chondrogenesis would be unlikely to be apparent in
such GATA-6 mutant embryos. Conditional GATA-6 knockouts
in chondrogenic lineages will be necessary to establish the
functional requirements for GATA-6 in chondrogenesis in vivo.
The present studies also demonstrate that GATA-6 alone is
not sufficient to change the differentiation status of immature
ATDC5 cells as determined by the expression of a panel of
chondrogenic genes representing different developmental
stages. However, this does not preclude GATA-6 having an
instructive role in the overall chondrogenic programme and may
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for full GATA-6 activity. It may also be relevant to note that
ATDC5 cells are clonal derivatives from a differentiating
teratocarcinoma (Atsumi et al., 1990) and uninduced ATDC5
cells are still already committed prechondrocyte progenitors
expressing a range of chondrogenic genes (data presented here
and in Chen et al., 2005). Thus, the action of GATA-6 may be
restricted to a yet earlier time-point in the chondrogenic
programme. In this context, it is noteworthy that the ability of
SOX-9 to transactivate Col II in cultured rabbit articular
chondrocytes is differentiation-stage dependent (Kypriotou
et al., 2003).
As a first stage in identifying the mechanistic role of GATA-6
in chondrogenesis, we describe here the identification of the
GPCR, Gpr49, as a potential direct downstream target of GATA
regulation within prechondrocyte progenitors. GPCRs represent
a large class of integral membrane proteins, which play
important roles in a variety of biological processes and
pathologies (Hill, 2006; Tilakaratne and Sexton, 2005). Many
GPCRs have been implicated in the tumorigenesis and
metastasis of multiple cancers (Li et al., 2005), and 50% of
all modern drugs are estimated to target GPCRs (Sarramegn
et al., 2006). Gpr49 belongs to a small cluster of leucine-rich
G-protein-coupled receptors (LGR) for which natural ligands
are still unknown.
Our initial reasons for investigating Gpr49 as a potential
target of GATA-6 regulation in chondrogenesis were based on
our microarray analyses (Alexandrovich et al., 2006) and
observations that Gpr49 is associated with development of the
vertebral column. Specifically, it has been reported that Gpr49 is
expressed within the perichordal mesenchyme that gives rise to
the intervertebral discs (Hermey et al., 1999). However, by a
combination of topographical markers and serial sections with
Uncx4.1, it is clear that in the E12.5 embryos analyzed here,
vertebral column expression of Gpr49 (and GATA-6) is
confined to the prevertebrae rather than to the disks. Further,
we also show here that expression extends to PCCs within the
developing limb, suggesting a more widespread role for Gpr49
in chondrogenesis than hitherto reported.
The major phenotype of Gpr49 null mice is ankyloglossia,
where the tongue is fused to the floor of the oral cavity, resulting
in neonatal mortality due to failure of the mice to nurse ap-
propriately (Morita et al., 2004). No abnormalities of the limbs or
axial skeleton were reported. However, it has been shown that the
closely related GPCR, LGR-4 (Gpr49 was originally named
LGR-5 or Fex; Hermey et al., 1999; Hsu et al., 1998), is expressed
both within the prevertebrae and other cartilaginous elements of
E14 mouse embryos (Van Schoore et al., 2005), together with
bone and cartilage of newborn mice (Mazerbourg et al., 2004).
Sequence analyses of LGR-4 and -5 suggest that they may share
similar ligand-binding and signal transduction characteristics
(Hsu et al., 2000), and might therefore demonstrate some
functional redundancy within cells in which they are co-
expressed. Such redundancy would potentially explain the lack
of an obvious chondrogenic phenotype in the Gpr49 null mouse.
Subsequent to the original identification in our microarray
analysis, our combined data now strongly suggest that Gpr49 isa target of GATA-6. Thus, in addition to being co-expressed in
PCCs in vivo, we have shown by siRNA experiments that
GATA-6 knock-downs in P19 CL6 cells result in an approxi-
mate 90% reduction of Gpr49 RNA levels. Furthermore,
analysis of N160 kb of the Gpr49 gene locus from four mam-
malian species revealed two GATA-binding sites within the
highest region of conserved homology (only six GATA-binding
sites were found in conserved regions of the sequences
compared and, surprisingly, all were located within the large
first intron). Both of these sites were found to bind GATA-6 in
EMSAs, further suggesting that Gpr49 is directly regulated by
GATA-6 in vivo.
While GATA-6 was able to up-regulate Gpr49 in P19 CL6
cells, this was not reproduced in the chondrogenic ATDC5 cell
background even though both genes were expressed in the latter
and both were up-regulated during its early differentiation.
There are several possibilities for this but it may reflect the
greater potential of P19 CL6 cells in giving rise to a broader
range of mesodermal progenitors. However, although we cannot
exclude the possibility that GATA-6 is regulating Gpr49
expression in non-chondrogenic cell types in the inducing
P19 cultures, we think this is unlikely as essentially the only co-
expression domain between them in early mouse embryos
appears to be in prechondrocyte progenitor populations. We
therefore think it is more probable to be related to the absence in
ATDC5 cells of additional necessary factors present in P19 CL6
cells related to the differentiation status of the two cell lines, as
described above. Thus, it is possible that GATA-6 may be
involved in the initial activation of Gpr49 and/or regulation of
its expression at earlier stages of chondrogenesis than manifest
by even immature ATDC5 cells.
In addition to Gpr49, several other chondrogenic genes have
also been reported to contain GATA sites within their
promoters. Thus, consensus GATA-binding sequences have
been found in SOX-9 (Kanai and Koopman, 1999), cartilage-
derived retinoic acid-sensitive protein (CD-RAP) (Bosserhoff et
al., 1997), α2(I) collagen (Pallante et al., 1996) and Runx-1
(Ghozi et al., 1996). Although none of these sites have yet to be
functionally tested, the inclusion of Runx-1 here may be
particularly noteworthy. Runx-1 has recently been shown to
induce early chondrogenic lineages from mesenchymal pre-
cursors (Wang et al., 2005) and its expression is similar to that
of GATA-6 reported here (Smith et al., 2005). Runx-1 has also
been found to interact physically with GATA factors in
megakaryocyte differentiation (Elagib et al., 2003), but any
co-operation in chondrogenesis has yet to be investigated.
Clearly, such areas of investigation, together with further
characterisation of the target genes of GATA-6 and the
consequences of its tissue-restricted loss of function in these
developmental systems, will be important in placing this
important regulator of cell function in the hierarchy of events
in chondrogenesis.
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